Interim Report 2026
Filed with HKEX · Stock code 2190 · · 95 pages · English
CORPORATE INFORMATION 2 FINANCIAL AND BUSINESS HIGHLIGHTS 4 MANAGEMENT DISCUSSION AND ANALYSIS 5 CORPORATE GOVERNANCE AND OTHER INFORMATION 36 REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION 50 INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME 51 INTERIM CONDENSED CONSOLIDATED BALANCE SHEET 53 INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 55 INTERIM CONDENSED CONSO
Zylox-Tonbridge Medical Technology Co., Ltd. on 6ix
Earlier from Zylox-Tonbridge Medical Technology
- Zylox-Tonbridge Delivers Strong First-Half 2026 Results as International Revenue Surges 349%
- Zylox-Tonbridge Recognized as Most Honored Company in Extel 2026 Asia Executive Team Survey
- Zylox-Tonbridge Reports 2025 Annual Results with Revenue Exceeding RMB 1.06 Billion and Net Profit Up 143.7% Year-over-Year
- Zylox-Tonbridge to Acquire Equity Interest in A European Medical Device Company to Accelerate Expansion in the Global MedTech Market
- Zylox-Tonbridge Hosts Investor Open Day, Showcasing Innovation Pipeline and Global Growth Strategy
Later from Zylox-Tonbridge Medical Technology
- Next Day Disclosure Return
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow Zylox-Tonbridge Medical Technology into a list and get an email when it puts out news.
Follow Zylox-Tonbridge Medical Technology